Genomic/Proteomic PTB Network: UAB Clinical Core Center

早产仍然是围产期发病率和死亡率的主要原因， 继续增加，有效的干预措施，以防止早产仍然虚幻。调查人员 我们机构的妇女健康研究中心在以下方面提供了强有力的临床研究领导： 在这片区域25年了。我们已经成功地获得了数百万美元的联邦资金， 研究旨在提高我们对早产病理生理学的理解， 许多潜在的干预措施在前瞻性随机试验。我们团队的生产力 在早产及其预防领域出版了数百份出版物。我们的卓越表现- 高质量的精心设计的临床试验是众所周知的。Germane是我们在此应用中的特殊优势， 成功进行多中心试验，并在研究网络中发挥领导作用，包括 NICHD母胎医学单位网络，我们已经成为近15年的参与机构 年事实上，UAB在2010年的14个中心中的整体表现排名第一。 成员机构的最新客观排名。因此，我们认为我们特别好- 定位，不仅要有效地参与，而且要提供领导作为临床核心中心， 提出了基因组和蛋白质组网络。在本申请中，我们将详细描述我们的 成功的临床研究设施和基础设施我们还将强调我们有据可查的 优势包括患者增加和保留、高质量数据采集和输入、快速增加 启动新的试验、方案遵守、分析和出版生产力，以及在以下方面的合作成功： NICHD MFMU网络中的协议开发和实现，该网络似乎是一个模型， 这是新网络的基础。我们相信我们对这个项目的热情和承诺 我们相信，我们的资格将是非常有竞争力的考虑。

Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high- quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well- positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competative for consideration.